<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523701</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02081; ex20Manzini</org_study_id>
    <nct_id>NCT04523701</nct_id>
  </id_info>
  <brief_title>Diagnostic Role of the &quot;White Test&quot; With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection (BiLe -Trial)</brief_title>
  <acronym>BiLe</acronym>
  <official_title>Diagnostic Role of the &quot;White Test&quot; With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection- A Randomized Controlled Multicentric Superiority Trial- The BiLe-Trial (Bile Leakage Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giulia Manzini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Aarau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bile leakage (BL) is the most frequent complication after liver resection. This study is to&#xD;
      investigate the role of intraoperative administration of SMOFlipid 20% (fat emulsion which&#xD;
      allows intraoperative identification of open bile ducts at the liver resection surface when&#xD;
      it is administered retrograde through the cystic duct) in terms of prevention of&#xD;
      postoperative BL within 30 days after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bile leakage (BL) is the most frequent complication after liver resection leading to the need&#xD;
      of interventional drainage, endoscopic retrograde cholangio pancreatography (ERCP) or even&#xD;
      reoperation. Strategies leading to a reduction of the rate of this complication are valuable.&#xD;
      SMOFlipid 20% is a fat emulsion which is primary indicated for parenteral nutrition. Because&#xD;
      of its fatty content this solution is white. This allows the clear intraoperative&#xD;
      identification of open bile ducts at the liver resection surface when it is administered&#xD;
      retrograde through the cystic duct. Consequently, open bile ducts can be sutured preventing&#xD;
      the postoperative development of BL. If the rate of bile leakages can be reduced, resources&#xD;
      for interventions and relaparotomy will be saved. This study is to investigate intraoperative&#xD;
      administration of SMOFlipid 20% in terms of prevention of BL within 30 days after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized, controlled, observer and patient blinded multicentric (4 centres) superiority trial with 2 parallel study groups</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Patients, care providers and outcome assessors are blinded, the surgical team is not blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>rate of postoperative bile leakage</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>Comparison of the rate of postoperative bile leakage in the control and in the intervention group. This is a binary endpoint defined by the presence or absence of the bile leakage (yes or no). Bile leakage is defined as bilirubin concentration in the drain fluid at least 3 times the serum bilirubin concentration on or after postoperative day 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of the bile leakage (Grade A, B or C according to the definition by Koch et al).</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>The severity of bile leakage is classified according to its impact on patientsÂ´ clinical management. Grade A bile leakage causes no change in patients' clinical management. A Grade B bile leakage requires active therapeutic intervention but is manageable without relaparotomy, whereas in Grade C bile leakage relaparotomy is required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality other than related to the bile leakage</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>In-hospital mortality other than related to the bile leakage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-Hospital morbidity other than related to the bile leakage</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>In-Hospital morbidity other than related to the bile leakage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic retrograde cholangio pancreatography (ERCP) (yes/no)</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>Endoscopic retrograde cholangio pancreatography (ERCP) (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percutaneous Transhepatic Cholangio Drainage (PTCD) (yes/no)</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>Percutaneous Transhepatic Cholangio Drainage (PTCD) (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interventional drainage (yes/no)</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>Interventional drainage (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-operation (yes/no)</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>Re-operation (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) stay (in days)</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>Intensive care unit (ICU) stay (in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital stay (in days)</measure>
    <time_frame>within 30 days postoperative</time_frame>
    <description>Total hospital stay (in days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Bile Leakage</condition>
  <arm_group>
    <arm_group_label>Experimental Intervention (treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open bile ducts are identified by visual control of the liver resection surface combined with the direct injection in the cystic stump of 20-40ml of SMOFlipid 20% Fresenius Kabi Canada Ltd.; authorization number: 57231 (Swissmedic).&#xD;
SMOFlipid is a white oily emulsion containing soya oil and medium chain triglycerides as main active components, normally used as parenteral nutrition as complement for essential fat acids supplementation. In this study the &quot;white&quot; test (= the administration of SMOFlipid retrograde through the cystic duct) is made by injection of one or two 20cc syringes full of lipidic solution (SMOFlipid 20%) in the cystic stump, directing the flow to the intrahepatic ducts. Residual fat emulsion is washed out from the biliary tract by a low pressure infusion of 20 to 50 ml of saline solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Open bile ducts are identified in the control group by visual control of the liver resection surface combined with the use of white gauzes (standard procedure)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;white&quot; test&quot; (= the administration of SMOFlipid retrograde through the cystic duct)</intervention_name>
    <description>&quot;white&quot; test&quot; (= the administration of SMOFlipid retrograde through the cystic duct)</description>
    <arm_group_label>Experimental Intervention (treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who will receive an anatomical resection of two or more liver segments for&#xD;
             any reason with simultaneous cholecystectomy in elective Setting&#xD;
&#xD;
          -  Patients who will receive an anatomical resection of two or more liver segments for&#xD;
             any reason which already had a cholecystectomy if intraoperatively the cystic stump&#xD;
             can be identified and opened&#xD;
&#xD;
          -  Ability of subject to understand character and individual consequences of the clinical&#xD;
             Trial&#xD;
&#xD;
          -  Informed consent documented by signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous cholecystectomy if intraoperative it is not possible to identify the cystic&#xD;
             stump&#xD;
&#xD;
          -  Intraoperative hepatico-jejunostomy&#xD;
&#xD;
          -  Hypersensitivity to fish-, egg-, soybean or peanut protein or to any of the active&#xD;
             ingredients or excipients&#xD;
&#xD;
          -  Immunosuppression, pregnancy&#xD;
&#xD;
          -  Emergency liver resection because of traumatic liver rupture&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giulia Manzini, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of Aarau, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giulia Manzini, Dr. med.</last_name>
    <phone>+41-62-8389734</phone>
    <email>giulia.manzini@ksa.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Visceral Surgery, Cantonal Hospital of Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Manzini, Dr. med.</last_name>
      <phone>062-8389734</phone>
      <email>giulia.manzini@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Giulia Manzini, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Cristaudi, Dr. med.</last_name>
      <phone>091 811 7208</phone>
      <email>alessandra.cristaudi@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Alessandra Cristaudi, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Scheiwiller, Dr. med.</last_name>
      <phone>041 2054539</phone>
      <email>andreas.scheiwiller@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Scheiwiller, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignazio Tarantino, PD Dr. med.</last_name>
      <phone>071 4941312</phone>
      <email>Ignazio.tarantino@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Ignazio Tarantino, PD Dr. med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kantonsspital Aarau</investigator_affiliation>
    <investigator_full_name>Giulia Manzini</investigator_full_name>
    <investigator_title>Dr. med., Senior physician, Department of Visceral Surgery</investigator_title>
  </responsible_party>
  <keyword>Liver resection</keyword>
  <keyword>SMOFlipid 20%</keyword>
  <keyword>White Test</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SMOFlipid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

